PMC Links for GEO Profiles (Select 111685314) - PMC

Result Filters

Links from GEO Profiles

Items: 1 to 20 of 1249

<< First< Prev

Page of 63

Select item 110366621.

Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling

Shengqi Wang, Jing Li, Shicui Hong, Neng Wang, Shang Xu, Bowen Yang, Yifeng Zheng, Juping Zhang, Bo Pan, Yudie Hu, Zhiyu Wang

J Exp Clin Cancer Res. 2024; 43: 121. Published online 2024 Apr 23. doi: 10.1186/s13046-024-03050-7

PMCID:: PMC11036662

Article PDF–14M

Select item 110304622.

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells

Lisa Borkner, Andrew Kaiser, Willeke van de Kasteele, Reinhard Andreesen, Andreas Mackensen, John B. Haanen, Ton N. Schumacher, Christian Blank

Cancer Immunol Immunother. 2010 Aug; 59(8): 1173–1183. Published online 2010 Mar 27. doi: 10.1007/s00262-010-0842-0

PMCID:: PMC11030462

Article PDF–711K

Select item 110298393.

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

Juro Nakanishi, Yoshihiro Wada, Koichiro Matsumoto, Miyuki Azuma, Ken Kikuchi, Shoichi Ueda

Cancer Immunol Immunother. 2007 Aug; 56(8): 1173–1182. Published online 2006 Dec 22. doi: 10.1007/s00262-006-0266-z

PMCID:: PMC11029839

Article PDF–474K

Select item 110296714.

Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases

Bastian Dislich, Alexandra Stein, Christian A. Seiler, Dino Kröll, Sabina Berezowska, Inti Zlobec, José Galvan, Julia Slotta-Huspenina, Axel Walch, Rupert Langer

Cancer Immunol Immunother. 2017 Jun; 66(6): 777–786. Published online 2017 Mar 13. doi: 10.1007/s00262-017-1982-2

PMCID:: PMC11029671

Article PDF–1.3M

Select item 110295775.

Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer

Christian J. Maine, Nor Haslinda Abdul Aziz, Jayanta Chatterjee, Claudia Hayford, Nancy Brewig, Lynsey Whilding, Andrew J. T. George, Sadaf Ghaem-Maghami

Cancer Immunol Immunother. 2014 Mar; 63(3): 215–224. Published online 2013 Dec 3. doi: 10.1007/s00262-013-1503-x

PMCID:: PMC11029577

Article PDF–562K

Select item 110289706.

A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients’ survival in gastric cancer

Weili Wang, Ping Liao, Yijing He

Cancer Immunol Immunother. 2017 Oct; 66(10): 1379–1381. Published online 2017 May 24. doi: 10.1007/s00262-017-2017-8

PMCID:: PMC11028970

Article PDF–438K

Select item 110287517.

PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer

Riki Okita, Ai Maeda, Katsuhiko Shimizu, Yuji Nojima, Shinsuke Saisho, Masao Nakata

Cancer Immunol Immunother. 2017 Jul; 66(7): 865–876. Published online 2017 Mar 25. doi: 10.1007/s00262-017-1986-y

PMCID:: PMC11028751

Article PDF–1.1M

Select item 110287058.

Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma

Tatiana Salles de Souza Malaspina, Thaís Helena Gasparoto, Maria Renata Sales Nogueira Costa, Edgard Franco de Melo, Jr, Maura Rosane Valério Ikoma, José Humberto Damante, Karen Angélica Cavassani, Gustavo Pompermaier Garlet, João Santana da Silva, Ana Paula Campanelli

Cancer Immunol Immunother. 2011 Jul; 60(7): 965–974. Published online 2011 Mar 27. doi: 10.1007/s00262-011-1007-5

PMCID:: PMC11028705

Article PDF–635K

Select item 110283679.

Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma

Soo Jeong Nam, Young-Hoon Kim, Ji Eun Park, Young-shin Ra, Shin Kwang Khang, Young Hyun Cho, Jeong Hoon Kim, Chang Ohk Sung

Cancer Immunol Immunother. 2019 Feb; 68(2): 305–318. Published online 2018 Nov 27. doi: 10.1007/s00262-018-2278-x

PMCID:: PMC11028367

Article PDF–2.5M

Select item 1102831510.

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas

Lucie Duverger, Amélie Osio, Bernard Cribier, Laurent Mortier, Adèle De Masson, Nicole Basset-Seguin, Céleste Lebbé, Maxime Battistella

Cancer Immunol Immunother. 2019 Jun; 68(6): 951–960. Published online 2019 Apr 5. doi: 10.1007/s00262-019-02334-8

PMCID:: PMC11028315

Article PDF–926K

Select item 1102826611.

Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease

Georgia Karpathiou, Celine Chauleur, Sirine Hathroubi, Cyril Habougit, Michel Peoc’h

Cancer Immunol Immunother. 2018 Aug; 67(8): 1297–1303. Published online 2018 Jun 25. doi: 10.1007/s00262-018-2189-x

PMCID:: PMC11028266

Article PDF–1.6M

Select item 1102824012.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann

Cancer Immunol Immunother. 2018 Mar; 67(3): 403–412. Published online 2017 Nov 17. doi: 10.1007/s00262-017-2093-9

PMCID:: PMC11028240

Article PDF–1.1M

Select item 1102820913.

Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer

Fabio Grizzi, Angelo Castello, Dorina Qehajaj, Luca Toschi, Sabrina Rossi, Daniela Pistillo, Valentina Paleari, Giulia Veronesi, Pierluigi Novellis, Simona Monterisi, Rossana Mineri, Daoud Rahal, Egesta Lopci

Cancer Immunol Immunother. 2019 Sep; 68(9): 1537–1545. Published online 2019 Sep 3. doi: 10.1007/s00262-019-02387-9

PMCID:: PMC11028209

Article PDF–984K

Select item 1102820714.

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer

Yusuke Okuma, Tsunekazu Hishima, Jumpei Kashima, Sadamu Homma

Cancer Immunol Immunother. 2018 Mar; 67(3): 495–505. Published online 2017 Dec 14. doi: 10.1007/s00262-017-2103-y

Correction in:: Cancer Immunol Immunother. 2018 Sep; 67(9): 1477–1479.

PMCID:: PMC11028207

Article PDF–1.8M

Select item 1102812115.

Clinicopathologic implications of CD8⁺/Foxp3⁺ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients

Ming-Xiang Zou, Ke-Miao Guo, Guo-Hua Lv, Wei Huang, Jing Li, Xiao-Bin Wang, Yi Jiang, Xiao-Ling She

Cancer Immunol Immunother. 2018 Feb; 67(2): 209–224. Published online 2017 Oct 20. doi: 10.1007/s00262-017-2080-1

PMCID:: PMC11028121

Article PDF–1.4M

Select item 1102768716.

Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor

Valentine Suteau, Alexandre Collin, Philippe Menei, Patrice Rodien, Marie-Christine Rousselet, Claire Briet

Cancer Immunol Immunother. 2020 Oct; 69(10): 2053–2061. Published online 2020 May 22. doi: 10.1007/s00262-020-02611-x

PMCID:: PMC11027687

Article PDF–1.0M

Select item 1102767317.

Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone

Jasna Metovic, Laura Annaratone, Alessandra Linari, Simona Osella-Abate, Chiara Musuraca, Francesca Veneziano, Chiara Vignale, Luca Bertero, Paola Cassoni, Nicola Ratto, Alessandro Comandone, Giovanni Grignani, Raimondo Piana, Mauro Papotti

Cancer Immunol Immunother. 2020 Sep; 69(9): 1905–1916. Published online 2020 May 6. doi: 10.1007/s00262-020-02594-9

PMCID:: PMC11027673

Article PDF–1.5M

Select item 1102766618.

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Mario Sanchez-Canteli, Rocio Granda-Díaz, Nagore del Rio-Ibisate, Eva Allonca, Fernando López-Alvarez, Jackeline Agorreta, Irati Garmendia, Luis M. Montuenga, Juana M. García-Pedrero, Juan P. Rodrigo

Cancer Immunol Immunother. 2020 Oct; 69(10): 2089–2100. Published online 2020 May 24. doi: 10.1007/s00262-020-02604-w

PMCID:: PMC11027666

Article PDF–1004K

Select item 1102765919.

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

Martin F. Orth, Veit Leonhard Buecklein, Eric Kampmann, Marion Subklewe, Elfriede Noessner, Florencia Cidre-Aranaz, Laura Romero-Pérez, Fabienne Sophie Wehweck, Lars Lindner, Rolf Issels, Thomas Kirchner, Annelore Altendorf-Hofmann, Thomas G. P. Grünewald, Thomas Knösel

Cancer Immunol Immunother. 2020 Jul; 69(7): 1353–1362. Published online 2020 Mar 28. doi: 10.1007/s00262-020-02552-5

PMCID:: PMC11027659

Article PDF–1.1M

Select item 1102746520.

Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients

Yusuke Omura, Yuji Toiyama, Yoshinaga Okugawa, Chengzeng Yin, Tsunehiko Shigemori, Kurando Kusunoki, Yukina Kusunoki, Shozo Ide, Tadanobu Shimura, Hiroyuki Fujikawa, Hiromi Yasuda, Junichiro Hiro, Masaki Ohi, Masato Kusunoki

Cancer Immunol Immunother. 2020 Dec; 69(12): 2533–2546. Published online 2020 Jun 23. doi: 10.1007/s00262-020-02645-1